FrançaisAre analysts right about Regeneron Pharmaceuticals (REGN)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Regeneron Pharmaceuticals, we replayed every analyst price target of the past 12 months and measured the real outcome: 49% were profitable, average return +11% (311 calls). At 3 months: +2% average return (42% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| RBC Capital | 22 | 9% | -32% |
| Truist Securities | 20 | 50% | +5% |
| Morgan Stanley | 19 | 68% | +12% |
| B of A Securities | 15 | 73% | +43% |
| Barclays | 15 | 47% | +8% |
Valuation
Is Regeneron Pharmaceuticals overvalued, and is it a good time to buy Regeneron Pharmaceuticals right now? If you're wondering, here's a recap to make up your own mind: Regeneron Pharmaceuticals's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Regeneron Pharmaceuticals | Sector median (Health Care) |
|---|---|---|
| P/E | 20.2 | 29.4 |
| Forward P/E | 13.3 | 17.1 |
| Net margin | 28% | 12% |
👉 Regeneron Pharmaceuticals trades below its sector median (20.2 vs 29.4) — potentially undervalued, or lower expected growth.
📖 P/E, PEG, margin…: see the glossary
💵 Dividend : Regeneron Pharmaceuticals pays about $3.64/share/yr → 0.58% yield. what is this?
Frequently asked questions
Is Regeneron Pharmaceuticals a buy right now?
The analyst consensus on Regeneron Pharmaceuticals (REGN) is "Buy" (40 bullish, 1 bearish calls over 12 months). This is not advice: historically, 49% of their targets on this stock turned out profitable over 1 year.
What is Regeneron Pharmaceuticals's price target?
The median 12-month price target is $824 (+2% vs $808), ranging from $185 to $1,030 (17 analysts).
Are analysts accurate on Regeneron Pharmaceuticals?
Over 1 year, 49% of analyst targets on Regeneron Pharmaceuticals were profitable, for an average return of +11% (across 311 timestamped calls). This is JPI Invest's accuracy metric.
What is the Regeneron Pharmaceuticals stock forecast?
Analysts target a median of $824 within 12 months, i.e. +2% vs the current price. The most bullish targets $1,030, the most cautious $185.
What is the Regeneron Pharmaceuticals stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $824, +2%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (49%), and the stock's past trajectory.
Is Regeneron Pharmaceuticals overvalued?
Its P/E is 20.2, forward P/E 13.3. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Regeneron Pharmaceuticals →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.